Trametinib in combination with SHP099 caused substantial tumor regression also in TNBC xenograft models [195] and induced profound growth inhibition of TNBC cell lines harboring a spectrum of molecular alterations, such as EGFR-amplifications (MDA-MB-468 and BT-20), RAS mutations (MDA-MB-231, Hs 578T, and SUM159), and NF1 mutation (MDA-MB-157) [196]. Here, NF1 is linked to neoplasm.